Wedbush raised the firm’s price target on Pharvaris (PHVS) to $27 from $25 and keeps an Outperform rating on the shares. The firm notes management reiterated key clinical milestones which includes potential readout timing for the RAPIDe-3 study of deucrictibant in Q1 2026, and CHAPTER-3 remains on track for the second half of 2026. Also notable in the update, Pharvaris secured tQT study waivers for both the XR and IR formulations, Wedbush adds.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris price target lowered to $25 from $28 at Cantor Fitzgerald
- Pharvaris: Strong Buy Rating Backed by Regulatory Success and Promising Clinical Progress
- Pharvaris reports Q1 EPS EUR (0.85) vs. EUR (0.52) last year
- Pharvaris Reports Q1 2025 Financials and Advances HAE Treatment Trials
- Pharvaris initiated with an Overweight at Cantor Fitzgerald